Welcome to our dedicated page for Novabay Pharma news (Ticker: NBY), a resource for investors and traders seeking the latest updates and insights on Novabay Pharma stock.
NovaBay Pharmaceuticals (NBY) delivers innovative non-antibiotic anti-infectives for ophthalmic care, wound management, and dermatological conditions. This page provides investors and healthcare professionals with timely updates on the company’s scientific advancements, regulatory milestones, and market strategies.
Access consolidated news about NBY’s Neutrox™ product line, including Avenova for chronic eye conditions, and developments in its Aganocide® compound research. Stay informed about financial disclosures, partnership announcements, and clinical trial outcomes through verified press releases and analysis.
Key updates include FDA submissions, international distribution expansions, and peer-reviewed study results. Our repository ensures efficient tracking of NovaBay’s progress in addressing antibiotic resistance challenges through its patented antimicrobial technologies.
Bookmark this page for direct access to NBY’s latest corporate communications. Check regularly for insights into commercialization efforts and research breakthroughs shaping the future of non-antibiotic therapies.
NovaBay Pharmaceuticals (NYSE American: NBY) has expanded the availability of its DERMAdoctor skincare products through two major U.S. online retailers, Target.com and Urbanoutfitters.com. This expansion aims to enhance customer access to DERMAdoctor’s innovative skincare solutions, which address issues like acne, aging, and sensitive skin. Target.com ranks as the fifth largest online retailer in the U.S., showcasing significant growth potential. NovaBay’s DERMAdoctor line comprises over 30 dermatologist-developed products sold through various channels, emphasizing effective solutions without prescription requirements.
NovaBay Pharmaceuticals (NYSE American: NBY) reported record sales of Avenova products during Amazon's Prime Day on July 12-13, showing a 27% increase from 2021 and a 48% increase from 2020. The sales achieved during this event set a new one-day record since Avenova's launch on Amazon in June 2019. CEO Justin Hall noted the impact of inflation on consumer behavior and expressed optimism about future growth through Amazon. Notably, Avenova Lid & Lash Spray has a strong customer rating of 4.5 stars from over 11,400 reviews.
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announced its participation in
NovaBay Pharmaceuticals reported a 46% increase in total sales for Q1 2022, totaling $2.6 million, driven by the acquisition of DERMAdoctor. Avenova Spray unit sales rose 15%, despite a decline in revenue from $1.6 million to $1.4 million due to unexpected returns. Gross margins fell to 58% from 75% in the prior year, attributed to these returns. Operating expenses increased to $3.9 million including costs related to DERMAdoctor. Net loss decreased to $111,000 from $1.5 million year-over-year.
NovaBay Pharmaceuticals (NBY) has announced the launch of next-generation skincare products as part of its popular product lines, Kakadu C and Calm Cool + Corrected. These new formulas incorporate anti-aging ingredients to target wrinkles, fine lines, and skin discoloration, specifically catering to both normal and sensitive skin types. The Kakadu C serum combines retinol with vitamin C, while the Bakuchiol-based Calm Cool + Corrected serum offers a gentle alternative suitable for sensitive skin. Both products aim to deliver visible results and enhance skin vitality.
NovaBay Pharmaceuticals (NBY) will announce its financial results for Q1 2022 on May 12, 2022, after market close, followed by a conference call at 4:30 p.m. ET. Participants can pre-register for immediate access or dial in live. A replay of the call will be available from two hours after its conclusion until June 2, 2022. NovaBay focuses on developing and selling products in the eyecare and skincare markets, notably its Avenova antimicrobial spray. The company recently acquired DERMAdoctor, enhancing its skincare portfolio.
NovaBay Pharmaceuticals (NBY) reports significant advancements following its acquisition of DERMAdoctor, enhancing its market presence in the eyecare and skincare sectors. The Avenova product line saw a 15% sales increase, with 74% of revenue from non-prescription sales. New innovative products are being introduced under Avenova and DERMAdoctor, leveraging a low-cost model for market testing. The company aims to tap into the growing global lash extension market, projected to reach $2.4 billion by 2031. Despite minor supply chain disruptions, NovaBay anticipates major growth in the latter half of 2022.
NovaBay Pharmaceuticals (NYSE: NBY) will showcase Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm on QVC's 'Get Ready, Gorgeous with Ali' on
NovaBay Pharmaceuticals has launched a new product, Hydrating Cleansing Oil, under the DERMAdoctor Calm Cool + Corrected brand. This soap-free, pH-balanced formula is designed to moisturize and remove makeup without drying the skin, specifically targeting dry, sensitive, or eczema-prone skin. Priced at
NovaBay Pharmaceuticals, Inc. (NBY) reported a 40% increase in fourth quarter net product revenue, totaling $2.6 million, primarily driven by strong sales of the Avenova spray. Avenova's sales were up 15% for the year, with unit sales growing 31%. The company also completed the acquisition of DERMAdoctor, diversifying its product line. While operating expenses rose to $4.6 million, net loss decreased to $0.9 million from $1.8 million year-over-year. Revenue for 2021 was $8.4 million, down from $9.9 million in 2020, due to a lack of PPE product sales.
